It is a good news that a vaccine trial has confirmed its safety as well as immunogenicity for the virus. It is remarkable that it has caused both humoral and cellular immunity against the pathogen. Since it is directed at the S protein, the antibody should have neutralizing characteristics.
https://www.nejm.org/doi/full/10.1056/NEJMoa2022483?query=featured_home
The only concern about this work might be that S protein could mutate if not so frequently as N protein. Such mutation not only could weaken the efficacy of the vaccine but also even cause the antibody dependent enhancement of infection as the vaccine of Dengue fever could elicit.
We could not be too optimistic for the future of vaccine development. But we should eagerly wait for a vaccine which recognizes the common structure of S protein of the virus and could work for any mutated virus.
No comments:
Post a Comment